Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

with MD Anderson Cancer Center and a number of institutions around the world. This study reported the impressive activity of the first BTK (Bruton's Tyrosine Kinase) inhibitor called PCI-32765 or ibrutinib. Ibrutinib belongs to a new category of drugs targeting the BCR (B-cell receptor) pathway, which appears very critical for B-cells and lymphoma cells' survival. Ibrutinib was very well tolerated and showed activity in almost three-fourths of the patients with very durable responses. Ibrutinib is currently under priority review by the FDA as an additional therapeutic treatment option. ("Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma" NEJM August 2013).

"These two new drugs represent great hope for patients with relapsed/refractory mantle-cell lymphoma and offer a terrific opportunity moving forward for treatments in combination or after conventional chemotherapy (as maintenance or consolidation), which will definitely improve the outcome of mantle-cell lymphoma patients," said Andre Goy, M.D., M.S.

Dr. Goy previously showed the first activity of bortezomib (proteasome inhibitor) and headed the trials which led to bortezomib approval as the first new drug ever approved by the FDA for relapsed/refractory mantle cell lymphoma.

"As one of the premier Lymphoma programs in the nation, we are committed to being at the forefront of cutting-edge research and treatment," said Andrew L. Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center and President of Regional Cancer Care Associates. "MCL-001 and the approval of lenalidomide represent a breakthrough in the treatment of mantle-cell lymphoma."

About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center at
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Deutschland, 31. Juli 2014  invendo medical ... („robotischen") Koloskopie-Systems für den Einmalgebrauch, verkündete heute, ... weltweit anerkannter Manager im Bereich Medizintechnik, als ... stößt. Logo - ... hochangesehener globaler Visionär der Medizintechnikbranche. Er war ...
(Date:7/31/2014)... July 31, 2014 Nutrastar International Inc. (OTCQB: ... supplier of premium branded consumer products, including commercially cultivated ... foods, today announced the signing of its first distributor ... expansion to Hubei Province ... Central China . The contract ...
(Date:7/31/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... $70.1 million for the second quarter ended June 30, ... revenue for the same period of 2013. ... Assist Systems were sold globally compared to 523 units ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12
... Who Take DHA Have Healthier Pregnancies, Fewer Premature Births, ... nutritional,experts from a European Union (EU) committee now recommend ... basis with a large amount,of DHA, an essential omega-3 ... growing array of health benefits, nutritional,supplementation of DHA is ...
... Agent Administered in First-In-Human Study to Cancer Patients, ... Pharmaceuticals, Inc.,today announced that its first-in-humans Phase 1 ... is designed to evaluate the safety,pharmacokinetic and pharmacodynamic ... tumors. Study sites include TGen Clinical Research at,Scottsdale ...
Cached Medicine Technology:European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day 2Prolexys Pharmaceuticals Initiates Phase 1 Study 2
(Date:7/31/2014)... Ottawa, Ontario (PRWEB) July 31, 2014 ... s deliver fitness to your home, which now includes ... certified personal trainers have been delivering fitness to clients ... Ottawa. Fitness on the Go is a Canadian owned ... to helping communities achieve a healthier and fitter lifestyle. ...
(Date:7/31/2014)... July 31, 2014 In a front-page ... pharmaceutical giant, Johnson & Johnson, is withdrawing its laparoscopic ... spread undetected cancer. This important story has also ... Today (7/31), the AP (7/30), the Pittsburgh Business Times ... is used during uterine procedures to, “slice up common ...
(Date:7/31/2014)... ARBORA new bill introduced in Congress with bipartisan support ... University of Michigan research, which could improve the health ... spend on the medicines and tests they need most. ... Diane Black and Earl Blumenauer, grew out of a ... the U-M,s Institute for Healthcare Policy and Innovation. It ...
(Date:7/31/2014)... 2014 Dr. Jeff Drake at Drake ... known chiropractors in the area and he has really made ... He is constantly working with new and return patients to ... Those who are in pain or experience daily suffering should ... those who have never visited Drake Chiropractic, Dr. Drake is ...
(Date:7/31/2014)... Long associated with enabling the proliferation of ... by Heat-Shock Factor 1 (HSF1) can also turn ... support malignant progression and metastasis. , The finding, ... the journal Cell , lends new insights ... diagnosis, prognosis, and management of cancer patients. ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go Grows to Ottawa 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Drake Chiropractic Offers Special to New Patients in Wichita 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 2Health News:Master HSF supports reprogramming of normal cells to enable tumor growth and metastasi 3
... suffering encountered by men who underwent surgery for hernia was ... delayed surgeries and felt almost no symptoms, after a period ... were also reported to be the same. Most men who ... either minimally symptomatic or asymptomatic. They usually wait until the ...
... doctors and pharmacists in the U.S. are not aware that ... drugs of the same brand name or a similar sounding ... U.S. Food and Drug Administration (FDA) //said medication name mix-ups ... buying and using the wrong medicine. ...
... 12 babies born in New South Wales are due to ... obstetricians working at the private hospitals. ,About 25% ... drugs to initiate labour. // ,The doctors when asked ... as they want that particular doctor to handle their pregnancy. ...
... upset and has sent a letter to the acting head of ... letter he had asked the FDA to provide a full account ... reveled that the tainted tissues were used for the patients in ... into the matter about the case of the Brooklyn funeral home ...
... incidence of Polio in Bihar state has led to much ... state stands unparalled with respect to the number of polio ... for provision of polio drops to children less than 5 ... recently. ,National Cadet Corps volunteers embarked on ...
... The Royal National Institute of Deaf People with collaboration with ... aims at checking the hearing capacity of 28 million people ... is estimated that more than 4 million people in United ... to be treated which requires early diagnosis. ,The ...
Cached Medicine News:Health News:Drug Name Confusion Makes Imports Dangerous: FDA 2Health News:New trend of birth induction is on the rise 2Health News:Bihar Health Officials Worried As Polio Cases Soar 2
Albumin (BCG). Storage temp: 15 -30 C. Linearity: 0.5 - 6.0 g/dl. Expected values: 3.5 - 5.5 g/dl. Available with calibrator. Performs 500 number of tests....
ASAT (GOT) FS (IFCC mod). For determination of ASAT (GOT) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
... The DRS 2000, a uniquely intelligent system, offers ... space saving, 2-level design. Up to 27 reservoirs ... give you the flexibility to tailor your staining ... Two start stations allow for continuous loading; The ...
Medicine Products: